Article

The adhesion molecule esam1 is a novel hematopoietic stem cell marker

Institute of Stem Cell Biology and Regenerative Medicine, Department of Pathology, Stanford University School of Medicine, California, USA.
Stem Cells (Impact Factor: 7.7). 03/2009; 27(3):653-61. DOI: 10.1634/stemcells.2008-0824
Source: PubMed

ABSTRACT Hematopoietic stem cells (HSCs) have been highly enriched using combinations of 12-14 surface markers. Genes specifically expressed by HSCs as compared with other multipotent progenitors may yield new stem cell enrichment markers, as well as elucidate self-renewal and differentiation mechanisms. We previously reported that multiple cell surface molecules are enriched on mouse HSCs compared with more differentiated progeny. Here, we present a definitive expression profile of the cell adhesion molecule endothelial cell-selective adhesion molecule (Esam1) in hematopoietic cells using reverse transcription-quantitative polymerase chain reaction and flow cytometry studies. We found Esam1 to be highly and selectively expressed by HSCs from mouse bone marrow (BM). Esam1 was also a viable positive HSC marker in fetal, young, and aged mice, as well as in mice of several different strains. In addition, we found robust levels of Esam1 transcripts in purified human HSCs. Esam1(-/-) mice do not exhibit severe hematopoietic defects; however, Esam1(-/-) BM has a greater frequency of HSCs and fewer T cells. HSCs from Esam1(-/-) mice give rise to more granulocyte/monocytes in culture and a higher T cell:B cell ratio upon transplantation into congenic mice. These studies identify Esam1 as a novel, widely applicable HSC-selective marker and suggest that Esam1 may play roles in both HSC proliferation and lineage decisions.

Download full-text

Full-text

Available from: Dietmar Vestweber, Jan 19, 2015
0 Followers
 · 
119 Views
  • Source
    • "We first analyzed the expression of markers used previously to distinguish HSCs and MPPs including CD34, Flt3 (also known as Flk2), Thy1, EPCR, and ESAM (Spangrude et al., 1988; Osawa et al., 1996; Christensen and Weissman, 2001; Adolfsson et al., 2005; Yang et al., 2005; Balazs et al., 2006; Ooi et al., 2009; Yokota et al., 2009). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Hematopoietic stem cells (HSCs) and multipotent hematopoietic progenitors (MPPs) are routinely isolated using various markers but remain heterogeneous. Here we show that four SLAM family markers, CD150, CD48, CD229, and CD244, can distinguish HSCs and MPPs from restricted progenitors and subdivide them into a hierarchy of functionally distinct subpopulations with stepwise changes in cell-cycle status, self-renewal, and reconstituting potential. CD229 expression largely distinguished lymphoid-biased HSCs from rarely dividing myeloid-biased HSCs, enabling prospective enrichment of these HSC subsets. Differences in CD229 and CD244 expression resolved CD150(-)CD48(-/low)Lineage(-/low)Sca-1(+)c-Kit(+) cells into a hierarchy of highly purified MPPs that retained erythroid and platelet potential but exhibited progressive changes in mitotic activity and reconstituting potential. Use of these markers, and reconstitution assays, showed that conditional deletion of Scf from endothelial cells and perivascular stromal cells eliminated the vast majority of bone marrow HSCs, including nearly all CD229(-/low) HSCs, demonstrating that quiescent HSCs are maintained by a perivascular niche.
    Cell stem cell 07/2013; 13(1):102-16. DOI:10.1016/j.stem.2013.05.014 · 22.15 Impact Factor
  • Source
    • "Antibodies were purified and conjugated by standard procedures in the Weissman laboratory, unless purchased commercially as stated above. Functional assessment of these populations have been performed in multiple studies [3]–[6], [8], [9], [11], [17], [18], [74], [76], [78]–[81]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Hematopoietic stem cells (HSC) are rare, multipotent cells capable of generating all specialized cells of the blood system. Appropriate regulation of HSC quiescence is thought to be crucial to maintain their lifelong function; however, the molecular pathways controlling stem cell quiescence remain poorly characterized. Likewise, the molecular events driving leukemogenesis remain elusive. In this study, we compare the gene expression profiles of steady-state bone marrow HSC to non-self-renewing multipotent progenitors; to HSC treated with mobilizing drugs that expand the HSC pool and induce egress from the marrow; and to leukemic HSC in a mouse model of chronic myelogenous leukemia. By intersecting the resulting lists of differentially regulated genes we identify a subset of molecules that are downregulated in all three circumstances, and thus may be particularly important for the maintenance and function of normal, quiescent HSC. These results identify potential key regulators of HSC and give insights into the clinically important processes of HSC mobilization for transplantation and leukemic development from cancer stem cells.
    PLoS ONE 01/2010; 5(1):e8785. DOI:10.1371/journal.pone.0008785 · 3.23 Impact Factor
Show more